Three-year study of tirzepatide shows that most patients only regain 5% or less from their lowest weight
New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around two-thirds of participants of the SURMOUNT-1 trial had only regained 5% or less of their so-called nadir (or lowest weight) three years after beginning treatment with tirzepatide.
Societies Decry HHS Obesity Med Decision; Diabetes-Autism Link; Ozempic ED Visits
(MedPage Today) — The Endocrine Society expressed disappointment over the Trump administration’s decision not to implement a proposal that would have allowed Medicare and Medicaid to cover anti-obesity medications.
Prior to Friday’s decision…
Drugs like Ozempic and Wegovy could significantly cut dementia risk
Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that they really could protect against dementia
Five things to know about semaglutide-based medications and addiction treatment
Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) agonists, this class of medications mimics a natural hormone the small intestine releases after you eat. They slow the movement of food through the gut and boost insulin production, increasing the feeling of fullness and suppressing appetite.
Switch to Tirzepatide in T2D More Effective Than Upping Dulaglutide Dose
(MedPage Today) — Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 receptor agonist, an open…
Ozempic weight loss is deemed less praiseworthy than lifestyle changes
People seem to be less impressed when others lose weight with the drug Ozempic than when they achieve it via lifestyle changes